 | | Vol. 10.20 – 26 May, 2021 |
| |
|
|
|
Scientists found that exosomal S100 calcium-binding protein A4 (S100A4) could induce the expression of osteopontin, along with other tumor metastasis/stemness-related genes.
[Signal Transduction and Targeted Therapy] |
|  | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The novel feedback loop among FMR1, circRNA-CHAF1A (circCHAF1A), miR-211-5p, and HOXC8 in glioma stem cells (GSCs) could facilitate the proliferation and tumorigenesis of glioma and GSCs
[Oncogene] |
|
|
|
| The authors found that the gamma-aminobutyric acid type A receptor π subunit (GABRP), as a membrane protein enriched in triple-negative breast cancer stem cells, interacted with epidermal growth factor receptor (EGFR) and significantly sustained its expression, resulting in stemness maintenance and chemotherapy resistance.
[Cancer Letters] |
|
|
|
| UPF1 enhanced chemoresistance to oxaliplatin in colorectal cancer, which may result from regulation of TOP2A activity and maintenance of stemness.
[Cell Death & Disease] |
|
|
|
| Using colon cancer patient-derived organoids and xenografts, researchers identified rare long-term label-retaining quiescent CSCs that could re-enter the cell cycle to generate new tumors.
[iScience] |
|
|
|
| Scientists explored the role of inhibition of MDR1 or ABCG2 in sensitizing liver CSCs to doxorubicin, the most frequently used chemotherapeutic agent in treating liver cancer.
[Scientific Reports] |
|
|
|
| The novel microtubule inhibitor, 5-(N-methylmaleimid-3-yl)-chromone suppressed the growth and sphere-forming activity of CSCs.
[Scientific Reports] |
|
|
|
| The authors reported a novel role of DYRK1A in maintaining tumor growth and stemness of oral/oropharyngeal squamous cell carcinoma cells.
[Experimental Cell Research] |
|
|
|
| Researchers examined CD97 function in primary patient-derived glioma stem cells obtained from five glioblastoma tumors, belonging to three major genetic subtypes.
[Journal of Neuro-Oncology] |
|
|
|
|
| Scientists summarize the targeted therapy approaches for the removal of leukemic stem cells (LSCs) through surface markers including immune checkpoint molecules, pathways influencing LSC survival, or the survival microenvironment of LSCs.
[Drug Discovery Today] |
|
|
|
| Investigators focus on the different antitumorigenic and therapeutic aspects of miR-1, including how it regulates tumor development and associated immunomodulatory functions.
[Seminars in Cell & Developmental Biology] |
|
|
|
|
| KAHR and Cancer Focus Fund, LP announced that Cancer Focus Fund is investing $5 million to finance a clinical trial of KAHR’s lead anti-CD47 candidate, DSP107, in blood cancers.
[KAHR (PR Newswire, LLC)] |
|
|
|
| AbbVie, Inc. announced that the European Commission has approved VENCLYXTO® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
[AbbVie, Inc.] |
|
|
|
|
| July 22 – 23, 2021
Virtual |
|
|
|
|
|
| | Columbia University Medical Center – New York, New York, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | City of Hope – Duarte, California, United States |
|
|
|
| | Cedars-Sinai – Los Angeles, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
